207 related articles for article (PubMed ID: 26174566)
21. Protein kinases as targets for cancer treatment.
Giamas G; Stebbing J; Vorgias CE; Knippschild U
Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
[TBL] [Abstract][Full Text] [Related]
22. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
[TBL] [Abstract][Full Text] [Related]
23. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
24. Mining the epigenetic landscape of tissue polarity in search of new targets for cancer therapy.
Atrian F; Lelièvre SA
Epigenomics; 2015; 7(8):1313-25. PubMed ID: 26646365
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
26. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor inhibitors: a patent review (2010 - present).
Li SN; Li HQ
Expert Opin Ther Pat; 2014 Mar; 24(3):309-21. PubMed ID: 24387079
[TBL] [Abstract][Full Text] [Related]
28. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
Chin YW; Han SY
Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
[TBL] [Abstract][Full Text] [Related]
29. Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy.
Claes B; Buysschaert I; Lambrechts D
Heredity (Edinb); 2010 Jul; 105(1):152-60. PubMed ID: 20389307
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
Zask A; Verheijen JC; Richard DJ
Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
[TBL] [Abstract][Full Text] [Related]
31. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
32. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
33. Investigative Approaches for Oral Delivery of Anticancer Drugs: A Patent Review.
Tariq M; Singh AT; Iqbal Z; Ahmad FJ; Talegaonkar S
Recent Pat Drug Deliv Formul; 2016; 10(1):24-43. PubMed ID: 26310247
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticle and targeted systems for cancer therapy.
Brannon-Peppas L; Blanchette JO
Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294
[TBL] [Abstract][Full Text] [Related]
35. Emerging patents for cancer-targeted nanomedicines.
Muthu MS; Pandey BL; Sahu AK; Rajesh CV
Pharm Pat Anal; 2012 May; 1(2):113-5. PubMed ID: 24236774
[No Abstract] [Full Text] [Related]
36. Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules.
Blancafort P; Jin J; Frye S
Mol Pharmacol; 2013 Mar; 83(3):563-76. PubMed ID: 23150486
[TBL] [Abstract][Full Text] [Related]
37. Chromatin modifying agents - the cutting edge of anticancer therapy.
Kwa FA; Balcerczyk A; Licciardi P; El-Osta A; Karagiannis TC
Drug Discov Today; 2011 Jul; 16(13-14):543-7. PubMed ID: 21664485
[TBL] [Abstract][Full Text] [Related]
38. Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors.
Liu Z; Gao Y; Li X
Expert Rev Anticancer Ther; 2019 Feb; 19(2):139-149. PubMed ID: 30470148
[No Abstract] [Full Text] [Related]
39. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
Abend A; Kehat I
Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
[TBL] [Abstract][Full Text] [Related]
40. Small molecule targeting of chromatin writers in cancer.
Conery AR; Rocnik JL; Trojer P
Nat Chem Biol; 2022 Feb; 18(2):124-133. PubMed ID: 34952934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
